Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Howard Druce

Allergy Somerville, NJ Medical Doctor

NPI 1871658476 CMS profile 312466

242 E Main St, Somerville, NJ 08876

Open in the dashboard

General payments

$37,486

63 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Howard Druce of Somerville, NJ is reported in the CMS Open Payments database as having received $37,486 across 63 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $3,115 5
2022 General $571 19
2021 General $4,353 15
2020 General $17,034 10
2019 General $12,413 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Howard Druce
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Howard Druce were reported at $0. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Howard Druce Allergy median Middle half National median
2019 $12,413 $506 $151–$1,337 $163
2020 $17,034 $409 $108–$1,162 $114
2021 $4,353 $549 $125–$1,485 $132
2022 $571 $666 $161–$1,594 $149
2023 $3,115 $780 $186–$1,916 $160
2024 $0 $1,031 $271–$2,196 $164
2025 $0 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Merck Sharp & Dohme Corporation $20,829 19 payments
  2. Allergan Inc. $10,500 3 payments
  3. Bayer Healthcare LLC $3,055 1 payment
  4. Mylan Inc. $1,221 1 payment
  5. Mylan Pharmaceuticals Inc. $675 1 payment
  6. GlaxoSmithKline, LLC. $313 14 payments
  7. ALK-Abello, Inc $260 6 payments
  8. Genzyme Corporation $259 6 payments
  9. OptiNose US, Inc. $173 7 payments
  10. Genentech USA, Inc. $149 1 payment
  11. Other $51 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Consulting Fee $34,911 20 payments
  2. Food and Beverage $1,353 42 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,221 1 payment
Products named General payments · program years 2019–2023
  1. MK-7264 $17,401 13 payments
  2. Dymista Respiratory and Allergy $1,221 1 payment
  3. DYMISTA Decongestants and other nasal preparations $675 1 payment
  4. DUPIXENT Immunology $476 9 payments
  5. NUCALA $313 14 payments
  6. Ragwitek $178 4 payments
  7. Xhance $173 7 payments
  8. Odactra $137 3 payments
  9. Grastek $125 2 payments
  10. DUPIXENT Immunology $43 3 payments
  11. Other $77 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

63 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record